Browsing Tag
BioAge Labs
3 posts
Can longevity biotech finally go mainstream — or is BioAge’s $250m shelf another warning sign of investor fatigue?
BioAge Labs (NASDAQ: BIOA) files a $250M shelf to fund aging-drug programs. Can disciplined financing revive investor faith in longevity biotech?
From IPO to $250M shelf: Can BioAge Labs keep investor faith in the race for anti-aging drugs?
BioAge Labs (NASDAQ: BIOA) files $250M mixed securities shelf to fuel its aging drug pipeline. See what it means for investors today.
Why BioAge Labs’ promising obesity drug trial of azelaprag came to an abrupt halt
BioAge Labs, a clinical-stage biopharmaceutical company focused on metabolic disease research, has announced the discontinuation of its STRIDES…